B7-H4 (VTCN1)
B7-H4 is a checkpoint-like protein that many breast, ovarian and endometrial tumours carry on their surface. Antibody-drug conjugates such as puxitatug samrotecan and HS-20089 use it as a docking site to deliver a chemotherapy payload. This dossier gathers the 2 products (0 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
The puxitatug samrotecan record calls B7-H4 a checkpoint-like protein enriched in breast, ovarian and endometrial cancers; in the corpus it is used as an ADC address rather than as a checkpoint to block.
- Triple-negative breast cancer
- Ovarian and endometrial cancer
- Tumour-associated macrophages
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →| Modality | Phase 3 | Phase 2 |
|---|---|---|
| ADC 2 |
Trials
Evidence ranking →| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Recruiting | A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | - | ||
| 3 | Recruiting | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) | - | ||
| 2 | Recruiting | A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer | - | ||
| 1/2 | Recruiting | A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) | - |
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Literature
Preprints →Query for this target: (TITLE:"B7-H4" OR ABSTRACT:"B7-H4" OR TITLE:"VTCN1" OR ABSTRACT:"VTCN1" OR TITLE:"B7H4" OR ABSTRACT:"B7H4" OR TITLE:"B7x" OR ABSTRACT:"B7x" OR TITLE:"B7S1" OR ABSTRACT:"B7S1" OR TITLE:"V-set domain containing T cell activation inhibitor 1" OR ABSTRACT:"V-set domain containing T cell activation inhibitor 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about B7-H4 (VTCN1), not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/b7h4.json. Licence CC BY-NC 4.0.